Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Over $72M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Published 06/06/2023, 14:22
Updated 06/06/2023, 15:40
© Reuters.  Over $72M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

© Reuters. Over $72M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Benzinga - The Dow Jones closed lower by around 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Lexicon Pharmaceuticals

  • The Trade: Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) 10% owner Invus Advisors Llc acquired a total 27,775,050 shares an average price of $2.60. To acquire these shares, it cost around $72.22 million.
  • What’s Happening: Lexicon Pharmaceuticals announced pricing of a $125 million public offering and concurrent private placement.
  • What Lexicon Pharmaceuticals Does: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.
Heliogen
  • The Trade: Heliogen, Inc. (NYSE: HLGN) 10% owner Patrick Soonshiong acquired a total of 180,012 shares at an average price of $0.25. The insider spent around $44.16 thousand to buy those shares.
  • What’s Happening: Heliogen posted a narrower-than-expected quarterly loss.
  • What Heliogen Does: Heliogen Inc is a concentrated solar energy system that is being developed to unlock the power of sunlight to replace fossil fuels.
ImmunityBio
  • The Trade: ImmunityBio, Inc. (NASDAQ: IBRX) Director Michael Blaszyk acquired a total of 71,915 shares at an average price of $2.75. To acquire these shares, it cost around $198.02 thousand. The company’s other Directors also purchased the company’s shares.
  • What’s Happening: ImmunityBio announced it received a complete response letter from the FDA on May 9th regarding its BLA for Anktiva in combination with Bacillus Calmette-Guérin.
  • What ImmunityBio Does: ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases.
Check This Out: Top 5 Financial Stocks That May Implode In Q2

Don’t forget to check out our premarket coverage here

Nanophase Technologies

  • The Trade: Nanophase Technologies Corporation (OTC: NANX) Chief Operating Officer Kevin Cureton acquired a total of 50,000 shares at an average price of $1.11. The insider spent $55.39 thousand to buy those shares.
  • What’s Happening: The company’s revenue for the first quarter was $9.5 million, representing a 16% year-over-year increase.
  • What Nanophase Technologies Does: Nanophase Technologies Corp is a U.S based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.